This page does not support translation languages. ×
秋元 雅之 秋元 雅之

秋元 雅之

AKIMOTO Masayuki




抗炎症剤の代謝、薬物間相互作用 後発品医薬品の製品評価の研究


1.Hori S., Kawata T., Kogure S., Yabu S., Mori K., and Akimoto M.*, Comparative release studies on suppositories using the basket, paddle, dialysis tubing and flow-through cell methods I. Acetaminophen in a lipophilic base suppository. Pharm Dev Technol. 2017 Feb;22(1):130-135.
2.Mori K., Hori S., Kawata T., Kogure S., Matsumoto k., Hasegawa T., Akimoto M.*, The in Vitro Release of Indomethacin from Suppositories: Effects of Bases and Comparison of Different Dissolution Methods. Chem Pharm Bull., 2017;65(7):674-677
3.Matsumoto K., Hasegawa T., Ohara K., Takei C., Akimoto M.*, Roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone. J. Pharm. Investig., 50, 71-79 (2020).
4.Matsumoto K., Hasegawa T., Ohara K., Takei C., Kamei T., Koyanagi J., Takahashi T., Akimoto M.*, A metabolic pathway for the prodrug nabumetone to the pharmacologically active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA) by non-cytochrome P450 enzymes. Xenobiotica 50, 783-792 (2020).
5.Matsumoto K., Hasegawa T., Ohara K., Kamei T., Koyanagi J., Akimoto M*., Role of human flavin-containing monooxygenase (FMO) 5 in the metabolism of nabumetone: Baeyer-Villiger oxidation in the activation of the intermediate metabolite, 3-hydroxy nabumetone, to the active metabolite, 6-methoxy-2-naphthylacetic acid in vitro. Xenobiotica 51, 155-166 (2021).
6.Shibata Y., Ohara K., Matsumoto K., Hasegawa T., Akimoto M.*, Total Anthocyanin Content, Total Phenolic Content, and Antioxidant Activity of Various Blueberry Cultivars Grown in Togane, Chiba Prefecture, Japan. J. Nutr. Sci. Vitaminol. 67, 201-209 (2021).